All In Biotech

Drug Trial Radar · NCT06680232

Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B

A Phase 1, Open-Label, First-in-Human, Dose Escalation (Part 1) and Expansion (Part 2) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of PBGENE-HBV in Participants With Chronic Hepatitis B (ELIMINATE-B)

Last checked: Nov 20, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Nov 14, 2024

Primary completion

Dec 2026

Study completion Jun 2027

Sponsor

Lead sponsor
Precision BioSciences, Inc.Industry
Sponsor type
Industry
First posted
Nov 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and antiviral activity of PBGENE-HBV in adult participants with chronic hepatitis B.

Conditions

  • HEPATITIS B CHRONIC

Interventions

  • PBGENE-HBVBiological

    PBGENE-HBV is an in vivo gene editing intervention based on a novel proprietary ARCUS® platform designed to potentially cure chronic hepatitis B virus (HBV) by eliminating cccDNA, the key source of replicating hepatitis B virus, while also inactivating integrated HBV DNA in hepatocytes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety to Assess Treatment-emergent Adverse Events (TEAEs)Time frame: 4 weeks after final dose

Locations

7 sites in 6 countries. Site status is shown where the registry gives one.

  • Massachusetts General Hospital/Harvard University

    Boston, Massachusetts · Recruiting

  • Hospital Beaujon

    Clichy, France, France · Recruiting

  • Queen Mary Hospital, The University of Hong Kong

    Hong Kong, Hong Kong, Hong Kong · Recruiting

  • ICS ARENSIA Exploratory Medicine SRL

    Chisinau, Moldova · Recruiting

  • New Zealand Clinical Research

    Auckland, New Zealand · Recruiting

  • ARENSIA Exploratory Medicine

    Bucharest, Romania, Romania · Recruiting

  • Arensia Exploratory Medicine in collaboration with County Clinical Emergency Hospital

    Cluj-Napoca, Romania, Romania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.